Prostate Cancer: Treatments by Stage
Hormone-Refractory Prostate Cancer (HRPC) continued...
Recent studies of chemotherapy regimens that include the drug docetaxel show they can improve survival by several months. Jevtana seems to work in some patients after docetaxel stops working. Mitoxantrone and Prednisone, as well as Xtandi ( enzalutamide), also have activity against prostate cancer in this setting.
Provenge is a vaccine for hormone-resistant prostate cancer that helps extend survival in men with hormone-resistant disease. Studies show that after starting treatment, about half of men are still alive two years later.
The medicine Zytiga is taken with the steroid Prednisone and is meant for men with hormone-refractory cancer that has spread to other parts of the body. Common side effects include high blood pressure, fatigue, joint swelling or pain, diarrhea, and fluid retention.
Bisphosphonates appear to be helpful for many men whose cancer has spread to the bones, reducing pain and even slowing cancer growth in many cases. Other medicines and techniques are also available to keep pain and other symptoms under control.
On the treatment horizon, researchers are testing several promising new agents for prostate cancer, including vaccines, monoclonal antibodies, and differentiating agents. Because medical experts' ability to treat hormone-refractory prostate cancer is still largely unsatisfactory, men are encouraged to explore these options by taking part in clinical trials.